Ani pharmaceuticals expands branded products portfolio through acquisition of sandoz inc. ndas

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (“ani”) (nasdaq:anip) today announced that it has acquired the new drug applications (“ndas”) for oxistat® lotion, veregen® ointment, and pandel® cream and the abbreviated new drug application (“anda”) for apexicon® e cream from sandoz inc. pandel® cream will be transitioned later upon receiving the requisite approvals. collectively, these products generated net revenues of $13.2 million in 2020. the acquisition was funded through borr
ANIP Ratings Summary
ANIP Quant Ranking